Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4683
−$0.0027 · -0.57%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Previous close
$0.4683
−$0.0027 · -0.57%
Regular session · ET · Market data may be delayed.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $0.4683
52-week range
Current $0.4683
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
59
Mixed
Risk
84
Extreme Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $0.4683
52-week range
Current $0.4683
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5M USD | — | 668K USD | — | — |
| Gross profit | −5M USD | — | −668K USD | — | — |
| Research and development | 176.07M USD | 200.93M USD | 142.72M USD | 104.75M USD | 212.78M USD |
| Selling, general, and administrative | 60.09M USD | 62.54M USD | 44.81M USD | 31.12M USD | 24.55M USD |
| Operating expenses | 236.16M USD | 263.46M USD | 187.53M USD | 135.87M USD | 237.32M USD |
| Interest income | 8.34M USD | 19.93M USD | 16.61M USD | 4.56M USD | — |
| Interest expense | 3.22M USD | — | — | — | — |
| Depreciation and amortization | 208K USD | 631K USD | 668K USD | 594K USD | 538K USD |
| Operating income | −241.16M USD | −263.46M USD | −188.19M USD | −135.87M USD | −237.32M USD |
| Net income | −236.93M USD | −243.79M USD | −235.93M USD | −130.9M USD | −237.31M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$4.50
860.92% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.57M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF1.5M0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 ETFIWM1.2M0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Russell 2000 ETFVTWO784.15K0.00%18B USD0.06%$112.21-1.26%
iShares Russell 2000 Growth ETFIWO501.59K0.00%14.25B USD0.24%$355.37-1.43%
iShares Biotechnology ETFIBB274.24K0.00%10.4B USD0.44%$203.34+0.12%
Vanguard Health Care ETFVHT263.98K0.00%22B USD0.09%$315.31+0.78%
Schwab U.S. Small-Cap ETFSCHA257.7K0.00%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
